Kura Oncology Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
Good afternoon, and welcome once again to TD Cowenâs Oncology Innovation Summit. Iâm Phil Nadeau, one of the biotech analysts here at TD Cowen, and itâs my pleasure to host a fireside chat with Kura Oncology. We have with us today Troy Wilson, President and CEO, and Mollie Leoni, Chief Medical Officer.
Troy, Iâll kick it to you to begin. Could you give us a brief overview of the state of the company -- its biggest strengths and biggest challenges?
And what do you think Kura needs to do to create and sustain value over the next year or two?
Questions & Answers
Sure. Yeah, thanks, Phil, and thanks for the opportunity to participate. In terms of the state of the company, we have ziftomenib in development for adult patients with relapsed/refractory NPM1âmutant AML.
As weâve reported, weâve had robust new patient starts and early launch momentum. Weâre advancing the program to ultimately
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
